FDA approves Daiichi Sankyo ' s new first-line AML drug quizartinib with boxed warning for heart disorders

Pa­tients with a rar­er form of acute myeloid leukemia now have a front­line treat­ment op­tion for the first time, thanks to the FDA’s ap­proval of Van­fly­ta (quizar­tinib), Dai­ichi Sankyo an­nounced late Thurs­day. Van­fly­ta has been ap­proved for FLT3-ITD-pos­i­tive AML pa­tients in…#myeloid #fda #daiichisankyo #aml #unlock
Source: Reuters: Health - Category: Consumer Health News Source Type: news